SCHEMBL515131

SCHEMBL515131

Cc1c(O)cc2oc(-c3ccc(O)cc3)cc(=O)c2c1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 0.80
KMT2A Q03164 6/20 0.76
GABRP O00591 4/20 0.76
GABRD O14764 4/20 0.76
GABRA1 P14867 4/20 0.76
GABRB1 P18505 4/20 0.76
GABRG2 P18507 4/20 0.76
GABRB3 P28472 4/20 0.76
GABRA5 P31644 4/20 0.76
GABRA3 P34903 4/20 0.76
GABRA2 P47869 4/20 0.76
GABRB2 P47870 4/20 0.76
GABRA4 P48169 4/20 0.76
GABRE P78334 4/20 0.76
GABRA6 Q16445 4/20 0.76
GABRG1 Q8N1C3 4/20 0.76
GABRG3 Q99928 4/20 0.76
GABRQ Q9UN88 4/20 0.76
CYP1A1 P04798 3/20 0.76
CYP1B1 Q16678 3/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6245328 0.89 ABCB1 (1.00) ABCB1KMT2AGABRPGABRDGABRA1
SCHEMBL30819155 0.88 ABCB1 (0.62) ABCB1KMT2AGABRPGABRDGABRA1
SCHEMBL5981301 0.87 ABCB1 (0.73) ABCB1KMT2AGABRPGABRDGABRA1
Scutellarein SCHEMBL28045966 0.87 KMT2A (0.94) ABCB1KMT2AGABRPGABRDGABRA1
Scutellarein SCHEMBL142093 0.87 KMT2A (1.00) ABCB1KMT2AGABRPGABRDGABRA1
Scutellarein SCHEMBL29692708 0.87 KMT2A (1.00) ABCB1KMT2AGABRPGABRDGABRA1
Scutellarein SCHEMBL29004586 0.87 KMT2A (1.00) ABCB1KMT2AGABRPGABRDGABRA1
SCHEMBL20718935 0.86 ABCB1 (0.71) ABCB1KMT2AGABRPGABRDGABRA1
SCHEMBL24088771 0.85 CBS (0.82) ABCB1KMT2AGABRPGABRDGABRA1
Scutellarein SCHEMBL1900314 0.85 KMT2A (0.97) ABCB1KMT2AGABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111067949-A Potentilla tormentosa total flavone effective part with lipopexia inhibiting effect, and preparation method and application thereof 延边大学 2020-04-28 CN claimed
EP-1503771-B1 SEDATIVE MATERIALS AND TREATMENTS UNIV STRATHCLYDE (GB) 2008-07-23 EP claimed
EP-1503771-A1 SEDATIVE MATERIALS AND TREATMENTS UNIVERSITY OF STRATHCLYDE (GB) 2005-02-09 EP claimed
WO-2003061678-A1 SEDATIVE MATERIALS AND TREATMENTS UNIVERSTIY OF STRATHCLYDE (GB) 2003-07-31 WO claimed
US-20250268968-A1 Vaporized Medicants and Methods of Use CQENS TECHNOLOGIES INC. (US) 2025-08-28 US disclosed
US-12311006-B2 Vaporized medicants and methods of use CQENS TECHNOLOGIES INC. (US) 2025-05-27 US disclosed
US-20250152601-A1 Compositions and Methods for the Treatment of Sexual Dysfunctions THE JONATHAN HURT LIVING TRUST (US) 2025-05-15 US disclosed
US-20240350476-A1 Smoking Cessation Aid Lucy Goods, Inc. 2024-10-24 US disclosed
US-20240180994-A1 HERBAL EXTRACT FORMULA FOR TREATING CORONAVIRUS INFECTION WAHI PHARMACEUTICALS INC. 2024-06-06 US disclosed
EP-4304621-A1 HERBAL EXTRACT FORMULA FOR TREATING CORONAVIRUS INFECTION Wahi Pharmaceuticals Inc. (US) 2024-01-17 EP disclosed
US-20230241148-A1 Vaporized Medicants and Methods of Use CQENS TECHNOLOGIES INC. 2023-08-03 US disclosed
US-11622985-B2 Vaporized medicants and methods of use CQENS TECHNOLOGIES, INC. (US) 2023-04-11 US disclosed
US-20090074708-A1 Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B) NATIONAL DEFENSE MEDICAL UNIVERSITY (TW) 2009-03-19 US disclosed
US-20080233242-A1 Antioxidant of Bamboo Leaves and Its Uses ZHANG YING 2008-09-25 US disclosed
EP-1503771-B1 SEDATIVE MATERIALS AND TREATMENTS UNIV STRATHCLYDE (GB) 2008-07-23 EP disclosed
EP-1503771-B1 SEDATIVE MATERIALS AND TREATMENTS UNIV STRATHCLYDE (GB) 2008-07-23 EP disclosed
EP-1503771-A1 SEDATIVE MATERIALS AND TREATMENTS UNIVERSITY OF STRATHCLYDE (GB) 2005-02-09 EP disclosed
EP-1503771-A1 SEDATIVE MATERIALS AND TREATMENTS UNIVERSITY OF STRATHCLYDE (GB) 2005-02-09 EP disclosed
WO-2003061678-A1 SEDATIVE MATERIALS AND TREATMENTS UNIVERSTIY OF STRATHCLYDE (GB) 2003-07-31 WO disclosed
WO-2003061678-A1 SEDATIVE MATERIALS AND TREATMENTS UNIVERSTIY OF STRATHCLYDE (GB) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080233242-A1 Antioxidant of Bamboo Leaves and Its Uses LPO, DBI, CAT ABCB1 3523/4885KMT2A 2496/4885GABRP 1873/4885
US-20240350476-A1 Smoking Cessation Aid NNMT, BHMT2, MAT2B ABCB1 2030/4885KMT2A 58/4885GABRP 2381/4885
US-20240180994-A1 HERBAL EXTRACT FORMULA FOR TREATING CORONAVIRUS INFECTION ACE2, ACE, HIRA ABCB1 3339/4885KMT2A 1157/4885GABRP 4619/4885
US-20090074708-A1 Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B) UGT2B7, UGT2B17, UGT1A10 ABCB1 18/4885KMT2A 4826/4885GABRP 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.